Real-world outcomes with tarlatamab in previously treated ES-SCLC

Dr Donald Bastin talks to ecancer about real-world findings from the Canadian CASCADE database evaluating tarlatamab in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC).

This interim analysis included 35 patients treated after at least two prior lines of therapy, many with brain or liver metastases. At a median follow-up of 8.2 months, real-world overall survival was 72% at three months and 57% at six months, with a median real-world progression-free survival of 2.5 months.

Dr Bastin discusses the effectiveness and safety findings, including cytokine release syndrome (CRS) in 68% of patients and immune effector cell-associated neurotoxicity syndrome (ICANS) in 17%.

The results offer insight into tarlatamab use in routine clinical practice, highlighting both its potential clinical activity and the need to interpret outcomes cautiously given the small cohort and limited follow-up.